A Phase 4 interventional study of Ferrous Sulfate in Chronic Kidney Insufficiency and Chronic Kidney Diseases, sponsored by Weill Medical College of Cornell University. Completed at 2 sites in United States. Open to participants aged 1 Year to 21 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Weill Medical College of Cornell University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 168 open to participants now, 215 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.
Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 596th largest by enrollment of the 819 interventional ones that give a count, is one of 53 that started in 2019, is one of 81 in phase 4, and was the 600th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →168 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:
University of Chicago · Sites in United States
Ages 18–70
Indiana University · Sites in United States
Ages 40–70
Bettina Mittendorfer · Sites in United States
Ages 18–100 · Healthy volunteers
University of Minnesota · Sites in United States
Ages 30–75
United Therapeutics · Sites in United States
Ages 40–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 1 Year to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
988 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 109 · Phase 2 185 · Phase 3 160 · Phase 4 81
First in 1988; this study’s year is marked. 53 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 72 across the 819 interventional studies, 125 across the 165 observational. Of the 699 that completed or were terminated, 345 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
372 of 988 have an industry lead sponsor. The 10 most frequent:
Weill Medical College of Cornell University is the lead sponsor of 893 studies on the registry; 165 are open to participants now.
Of its 124 completed or terminated interventional studies of FDA-regulated products, 95 (77%) have results posted.
Weill Medical College of Cornell University has 5 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
73 of the studies in Renal Insufficiency, Chronic with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03565913Phase 3University of Texas Southwestern Medical CenterPotential Therapeutic Role of Effervescent Calcium-Magnesium Citrate in Chronic Kidney Disease Stage V | 2026-12-01 |
| NCT06531824Phase 3Boehringer IngelheimEASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | 2026-12-31 |
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
Add all 73 to your calendar (.ics) → With an account.
Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a pilot clinical trial of oral iron therapy in children with chronic kidney disease (CKD) and mild anemia. Eligible children will be randomized into a standard of care (iron sulfate) arm vs. no iron therapy arm for 3 months. The outcomes will include muscle strength, physical activity, and changes in eating behavior, which will be measured at enrollment and at the end of the study period.
Key inclusion criteria:
Children with transferrin saturation ≤ 20% AND serum ferritin ≤ 100 ng/mL will be randomized into one of the arms
Key exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participant will receive oral iron therapy.
Drug: Ferrous Sulfate
Participant will not receive oral iron therapy for 3 months.
Oral iron will be given in the form of immediate-release iron sulfate, 3-6 mg/kg/day of elemental iron to children with body weight ≤43 kg, and 65 mg of elemental iron (325 mg of iron sulfate) to children with body weight \>43 kg.
Also known as: iron sulfate
Change in Muscle Strength
Hand-grip strength measured by a dynamometer.
Time frame: Baseline to 3 months
Change in Transferrin Saturation
Transferrin saturation (TSAT) is the percentage of transferrin iron-binding sites occupied by iron and is calculated as serum iron divided by total iron-binding capacity, multiplied by 100. Change in TSAT was calculated as the 3-month value minus the baseline value; positive values indicate an increase in TSAT.
Time frame: Baseline to 3 months
Change in Sedentary Time
Sedentary time (in minutes per day) will be measured by actigraphy. Actigraph is a monitor that looks like a wristband or a watch that measures and records body movements throughout the day. Participating children will wear actigraphs for 7 days in the beginning and 7 days at the conclusion of the study.
Time frame: Baseline to 3 months
Change in Percent Skeletal Muscle Mass
Skeletal muscle mass as a percentage of body weight was measured using bioelectrical impedance analysis. Change was calculated as the 3-month value minus the baseline value; positive values indicate an increase in the percentage of body weight represented by skeletal muscle mass.
Time frame: Baseline to 3 months
Change in Eating Behavior
Eating behavior was assessed using the 35-item parent-reported Children's Eating Behaviour Questionnaire (CEBQ). Items are scored from 1 (Never) to 5 (Always), with applicable items reverse-scored. Each subscale score is the mean of its constituent items and ranges from 1 to 5. Higher scores indicate greater expression of the respective eating behavior: greater Enjoyment of Food, greater Slowness in Eating, greater Emotional Undereating, or greater Food Fussiness. In the context of this study, greater Enjoyment of Food was considered favorable; greater Emotional Undereating and Food Fussiness were considered unfavorable. Slowness in Eating reflects slower eating and does not have an inherently favorable or unfavorable direction. Change was calculated as the 3-month score minus the baseline score.
Time frame: Baseline to 3 months
Change in Quality of Life: PROMIS Physical Activity Score
Physical activity was assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS uses a T-score metric in which 50 is the mean of the relevant reference population and 10 is the standard deviation. Higher Physical Activity T-scores indicate greater physical activity. The reported outcome is the change in T-score from baseline to 3 months, calculated as the 3-month T-score minus the baseline T-score.
Time frame: Baseline to 3 months
Change in Quality of Life: PROMIS Fatigue Score
Fatigue was assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS uses a T-score metric in which 50 is the mean of the relevant reference population and 10 is the standard deviation. Higher Fatigue T-scores indicate greater fatigue. The reported outcome is the change in T-score from baseline to 3 months, calculated as the 3-month T-score minus the baseline T-score.
Time frame: Baseline to 3 months
| Milestone | Oral Iron Therapy | No Oral Iron Therapy |
|---|---|---|
| Started | 10 | 11 |
| Completed | 10 | 11 |
| Not completed | 0 | 0 |
Hand-grip strength measured by a dynamometer.
| kg | Oral Iron Therapy | No Oral Iron Therapy |
|---|---|---|
| Change in Muscle Strength | -0.125 ± 3.116 | -0.5625 ± 2.589 |
Transferrin saturation (TSAT) is the percentage of transferrin iron-binding sites occupied by iron and is calculated as serum iron divided by total iron-binding capacity, multiplied by 100. Change in TSAT was calculated as the 3-month value minus the baseline value; positive values indicate an increase in TSAT.
| percent transferrin saturation | Oral Iron Therapy | No Oral Iron Therapy |
|---|---|---|
| Change in Transferrin Saturation | 7.06 ± 8.4 | 3.4 ± 6.4 |
Sedentary time (in minutes per day) will be measured by actigraphy. Actigraph is a monitor that looks like a wristband or a watch that measures and records body movements throughout the day. Participating children will wear actigraphs for 7 days in the beginning and 7 days at the conclusion of the study.
No measurements were reported for this outcome.
Skeletal muscle mass as a percentage of body weight was measured using bioelectrical impedance analysis. Change was calculated as the 3-month value minus the baseline value; positive values indicate an increase in the percentage of body weight represented by skeletal muscle mass.
| percent skeletal muscle mass | Oral Iron Therapy | No Oral Iron Therapy |
|---|---|---|
| Change in Percent Skeletal Muscle Mass | -2.63 ± 4.82 | 0.15 ± 5.29 |
Eating behavior was assessed using the 35-item parent-reported Children's Eating Behaviour Questionnaire (CEBQ). Items are scored from 1 (Never) to 5 (Always), with applicable items reverse-scored. Each subscale score is the mean of its constituent items and ranges from 1 to 5. Higher scores indicate greater expression of the respective eating behavior: greater Enjoyment of Food, greater Slowness in Eating, greater Emotional Undereating, or greater Food Fussiness. In the context of this study, greater Enjoyment of Food was considered favorable; greater Emotional Undereating and Food Fussiness were considered unfavorable. Slowness in Eating reflects slower eating and does not have an inherently favorable or unfavorable direction. Change was calculated as the 3-month score minus the baseline score.
| Score on a scale | Oral Iron Therapy | No Oral Iron Therapy |
|---|---|---|
| change in food enjoyment | -0.3 ± 0.5 | 0.04 ± 0.5 |
| change in eating slowness | 0.0 ± 0.3 | 0.1 ± 0.5 |
| change in emotional under-eating | 0.4 ± 0.1 | -0.4 ± 0.7 |
| change in food fussiness | 3.0 ± 0.7 | 3.1 ± 0.8 |
Physical activity was assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS uses a T-score metric in which 50 is the mean of the relevant reference population and 10 is the standard deviation. Higher Physical Activity T-scores indicate greater physical activity. The reported outcome is the change in T-score from baseline to 3 months, calculated as the 3-month T-score minus the baseline T-score.
| T-score points | Oral Iron Therapy | No Oral Iron Therapy |
|---|---|---|
| Change in Quality of Life: PROMIS Physical Activity Score | 6.92 ± 5.60 | 5.075 ± 13.54 |
Fatigue was assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS uses a T-score metric in which 50 is the mean of the relevant reference population and 10 is the standard deviation. Higher Fatigue T-scores indicate greater fatigue. The reported outcome is the change in T-score from baseline to 3 months, calculated as the 3-month T-score minus the baseline T-score.
| T-score points | Oral Iron Therapy | No Oral Iron Therapy |
|---|---|---|
| Change in Quality of Life: PROMIS Fatigue Score | -4.62 ± 12.25 | 4.60 ± 9.71 |
Collected over From randomization until end of follow-up in 3 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Oral Iron Therapy | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| No Oral Iron Therapy | 0/11 (0%) | 0/11 (0%) | 0/11 (0%) |
| Age, Continuous(years) | Oral Iron Therapy | No Oral Iron Therapy | Total |
|---|---|---|---|
| Mean | 12.8 ± 6.2 | 13.1 ± 2.8 | 12.9 ± 4.7 |
| Sex: Female, Male(Participants) | Oral Iron Therapy | No Oral Iron Therapy | Total |
|---|---|---|---|
| Female | 4 | 3 | 7 |
| Male | 6 | 8 | 14 |
| Race/Ethnicity, Customized(Participants) | Oral Iron Therapy | No Oral Iron Therapy | Total |
|---|---|---|---|
| Black race | 1 | 5 | 6 |
| Non-Black race | 9 | 6 | 15 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2019 to primary completion in Jun 2023, 50 months.
Results were first posted in Nov 2026, 3 years 4 months after primary completion.
Of 101 non-industry phase 4 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 65. This study's 50 months is close to that.
Counting every sponsor, half of 117 studies reached it within 43 months; a quarter within 22 and three quarters within 65.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Dec 2028 → Jun 2023 and completion Dec 2028 → Jun 2023.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferrous sulfate
Renal Insufficiency, Chronic →
Weill Medical College of Cornell University →